Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.

Cardiovasc Diabetol · 2019 · PMC6408833 · PMID 30851731

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

showed a trendp = 0.14not close (p > 0.1)

In a multivariate Cox regression model adjusted with age, gender and indication angiography, DM treated with insulin showed a trend as predictor for both MACE and TLF (HR 2.01; 95% CI 0.80–5.04; p = 0.14 and HR 2.54; 95% CI 0.93–6.97; p = 0.07 respectively), while absence of postdilatation showed a trend as predictor for TLF (HR 0.40; 95% CI 0.15–1.07; p = 0.07) as is presented in Table 4 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.